登录 注册 会员服务 联系我们

Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model

  • Published:2016 Issue:5 Volume:39 Page:705-711
  • ISSN:0918-6158
  • Container-title:Biological & Pharmaceutical Bulletin
  • language:en
  • Short-container-title:Biol. Pharm. Bull.

Author:

Kimura Koji1,Kanehira Naomi1,Takayanagi Risa1,Minohara Hideto2,Homma Masato3,Yamada Yasuhiko1

Affiliation:

1. Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

2. Department of Pharmacy, University of Tsukuba Hospital

3. Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Reference15 articles.

1. 1) Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am. J. Med., 116, 546–554 (2004).

2. 2) Ribeiro RC, Pui CH. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin. Lymphoma, 3, 225–232 (2003).

3. 3) Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, Pieters R, Uyttebroeck A. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin’s lymphoma in four European countries. Leuk. Lymphoma, 44, 77–83 (2003).

4. 4) Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, Herbrecht R, Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma. results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J. Clin. Oncol., 21, 4402–4406 (2003).

5. 5) Navolanic PM, Pui CH, Larson RA, Bishop MR, Pearce TE, Cairo MS, Goldman SC, Jeha SC, Shanholtz CB, Leonard JP, McCubrey JA. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia, 17, 499–514 (2003).
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3